By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Orexigen Therapeutics, Inc. 

48 Wall Street
Suite 1100
New York  New York  10005  U.S.A.
Phone: 212-918-4650 Fax: 212-918-4801


SEARCH JOBS


Industry
Biotechnology






Company News
Orexigen (OREX) Reports Financial Results For The First Quarter Ended March 31, 2017 5/10/2017 10:40:58 AM
Orexigen (OREX) Announces Commercialization And Distributorship Arrangement With Navamedic ASA For Mysimba (Naltrexone Hcl / Bupropion Hcl Prolonged Release) In Five Nordic Countries 5/2/2017 6:38:07 AM
Orexigen (OREX) To Provide Business Update And Discuss First Quarter 2017 Financial Results On May 9, 2017 4/26/2017 10:35:31 AM
Orexigen (OREX) Announces New Drug Submission For Contrave In Canada 4/25/2017 7:55:30 AM
Orexigen (OREX) Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2016 3/29/2017 8:38:55 AM
Orexigen (OREX) Announces Commercialization And Distributorship Agreement With Bruno Farmaceutici For Mysimba (Naltrexone Hcl / Bupropion Hcl Prolonged Release) In Italy 3/28/2017 6:26:23 AM
Orexigen (OREX) To Provide Business Update And Discuss Fourth Quarter And Year End 2016 Financial Results On March 28, 2017 3/8/2017 11:32:59 AM
Orexigen (OREX) Release: Company Announces Spanish Launch Of Mysimba (Naltrexone Hcl / Bupropion Hcl Prolonged Release) In Partnership With Laboratorios Farmace┬┤Uticos Rovi, S.A. 1/25/2017 8:27:59 AM
Orexigen (OREX) Announces Publication Of Contrave (Naltrexone Hcl And Bupropion Hcl Extended-Release Tablets) Real-World Study Results In "Obesity" 1/6/2017 7:03:27 AM
Orexigen (OREX) Highlights Key Business Priorities For 2017 1/5/2017 9:59:13 AM
12345678910...
//-->